IFN-γ-mediated prevention of graft-versus-host disease: Pharmacodynamic studies and influence on proliferative capacity of chimeric spleen cells

Bone Marrow Transplantation

Volumn 22, Issue 10, 1998, Pages 1005-1010

  Brok, H P M ^a   Vossen, J M ^b   Heidt, P J ^a  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

BMT; GVHD; IFN

Indexed keywords

CONCANAVALIN A; CYTOKINE; GAMMA INTERFERON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CELL STIMULATION; CHIMERA; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GRAFT VERSUS HOST REACTION; IMMUNITY; IMMUNOCOMPETENT CELL; INTRAPERITONEAL DRUG ADMINISTRATION; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; SURVIVAL; T LYMPHOCYTE;

EID: 0031784864     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701478     Document Type: Article

References (54)

1. Van Bekkum DW. Graft-versus-Host Disease. In: Van Bekkum DW, Löwenberg B (eds). Bone Marrow Transplantation. Marcel Dekker: New York, 1985, pp 147-212.
2. Vogelsang VB, Hess AD. Graft-versus-host disease: new directions for a persistent problem. Blood 1994; 84: 2061- 2067.
3. Gale RP, Bortin MM, Van Bekkum DW et al. Risk factors for acute graft-versus-host disease. Br J Haematol 1987; 67: 397-406.
4. Clift RA, Storb R. Histoincompatible bone marrow transplants in humans. Annu Rev Immunol 1987; 5: 43-64.
5. Anasetti C, Amos D, Beatty PG et al. Effect of HLA compatibility on engraftment of bone marrow transplantation in patients with leukemia or lymphoma. New Engl J Med 1989; 320: 197-204.
6. Cohen J. Cytokines as mediators of graft-versus-host disease. Bone Marrow Transplant 1988; 3: 193-197.
7. Jadus MR, Wepsic HT. The role of cytokines in graft-versus- host reactions and disease. Bone Marrow Transplant 1992; 10: 1-14.
8. Ferrera JM. Cytokine dysregulation as a mechanism of graft- versus-host disease. Curr Opin Immunol 1993; 5: 794-799.
9. Antin JH, Ferrara JLM. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 12: 2964-2968.
10. Nestel FP, Price KS, Seemayer TA, Lapp WS. Macrophage priming and lipopolysaccharide triggered release of tumor necrosis factor α during graft-versus-host disease. J Exp Med 1992; 175: 405-413.
11. Niederwieser D, Herold M, Woloszczuk W et al. Endogenous IFN-gamma during human bone marrow transplantation. Transplantation 1992; 50: 620-625.
12. Mowat AMcI. Antibodies to IFN-γ prevent immunological mediated intestinal damage in murine graft-versus-host reaction. Immunology 1989; 68: 18-23.
13. Anasetti C, Martin PJ, Storb R et al. Prophylaxis of graft- verus-host disease by administration of the murine anti-IL-2 receptor antibody 2A3. Bone Marrow Transplant 1991; 7: 375-381.
14. Massumoto C, Benyunes MC, Sale G et al. Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy. Bone Marrow Transplant 1996; 17: 351-356.
15. Via C, Rus V, Gately MK, Finkelman FD. IL-12 stimulates the development of acute graft-versus-host disease in mice that would normally develop chronic, autoimmune graft-versus- host disease. J Immunol 1994; 153: 4040-4047.
16. Williamson E, Garside P, Bradley JA, Mowat AMcI. IL-12 is a central mediator of acute graft-versus-host disease in mice. J Immunol 1996; 156: 689-699.
17. McCarthy PL, Abhyankar S, Neben S et al. Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood 1991; 78: 1915-1918.
18. Holler E, Kolb HJ, Möller A et al. Increased serum levels of tumor necrosis factor a precede major complications of bone marrow transplantation. Blood 1990; 75: 1011-1016.
19. Piguet P-F, Grau GE, Allet B, Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med 1987; 166: 1280-1289.
20. Brok HPM, Heidt PJ, Van der Meide PH et al. Interferon-γ prevents graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Immunol 1993; 151: 6451- 6459.
21. Sykes M, Rommick ML, Hoyles KA, Sachs DH. In vivo administration of interleukin 2 plus T-cell depleted syngeneic marrow prevents graft-versus-host disease and permits alloengraftment. J Exp Med 1990; 171: 645-658.
22. Sykes M, Abraham VS. The mechanism of IL-2-mediated pretection against GVHD in mice. II Protection occurs independently of NK/LAK cells, Transplantation 1992; 53: 1063- 1070.
23. + T cell activity. J Immunol 1993; 150: 197-205.
24. Abraham VS, Sachs DH, Sykes M. Mechanism of protection from graft-versus-host disease mortality by IL-2. III. Early reduction in donor T cell subsets and expansion of a CD3+CD4-CD8- cell population. J Immunol 1992; 148: 3746-3752.
25. Szebeni J, Wang MG, Pearson DA et al. IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host disease. Transplantation 1994; 58: 1385- 1393.
26. Sykes M, Szot GL, Nguyen PL, Pearson DA. Interleukin-12 inhibits murine graft-versus-host disease. Blood 1995; 86: 2429-2438.
27. Brok HPM, Vossen JM, Heidt PJ. Interferon-γ mediated prevention of graft-versus-host disease: development of immune competent and allo-tolerant T cells in chimeric mice. Bone Marrow Transplant 1997; 19: 601-606.
28. Heidt PJ, Vossen JM. Experimental and clinical gnotobiotics: influence of the microflora on graft-versus-host disease after allogeneic bone marrow transplantation. J Med 1992; 23: 161-173.
29. Van Bekkum DW, Roodenburg J, Heidt PJ, Van der Waaij D. Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora. J Natl Cancer Inst 1974; 52: 401-404.
30. Zurcher C, Van Bekkum DW. Pathology of Radiation chimeras. In: Van Bekkum DW, Löwenberg B (eds). Bone Marrow Transplantation, Biological Mechanisms and Clinical Practice. Marcel Dekker: New York, 1985, pp 213-310.
31. Van den Engh G, Visser J, Trask B. Identification of CFU-s by scatter measurements on a light activated cell sorter. In: Baum SJ, Ledney GD (eds). Experimental Hematology Today. Springer Verlag: New York, 1978, pp 19-26.
32. Okita K, Kaneko T. The potential of interferons in malignant disease. Drugs 1990; 39: 1-6.
33. Vadjan-Raj S, Al-Katib A, Bhalla R et al. Phase I trial of recombinant interferon gamma in cancer patients. J Clin Oncol 1986; 4: 137-146.
34. Mahmoud HH, Pui C-H, Kennedy W et al. Phase I study of recombinant human interferon gamma in children with relapsed acute leukemia. Leukemia 1992; 6: 1181-1184.
35. Van der Meide PH, Dubbeld M, Vijverberg K et al. The purification and characterization of rat gamma-interferon by use of two monoclonal antibodies. J Gen Virol 1986; 67: 1059-1071.
36. Sicher SC, Chung GW, Vazquez MA, Lu CY. Augmentation or inhibition of IFN-γ-induced MHC class II expression by lipopolysaccharides. The roles of TNF-α and nitric oxide, and the importance of the sequence of signalling. J Immunol 1995; 155: 5826-5834.
37. Zanetti G, Heumann D, Gerain J Kohler J et al. Cytokine production after intravenous or peritoneal gram-negative bacterial challenge in mice. Comperative protective efficacy of antibodies to tumor necrosis factor α and to lipopolysaccharide. J Immunol 1992; 148: 1890-1897.
38. Billiau A. Gamma-interferon: the match that lights the fire? Immunol Today 1988; 9: 37-40.
39. Denis M, Ghadirian E. Murine hypersensitivity pneumonitis- Bidirectional role of interferon-gamma. Clin Exp Allergy 1992; 22: 783-792.
40. Herve P, Flesch M, Tiberghien P et al. Phase I-II trail of a monoclonal anti-tumor necrosis factor α antibody for the treatment of refractory severe acute graft-versusthost disease. Blood 1992; 79; 3362-3368.
41. Vallera DA, Taylor PA, Vannice JL et al. Interleukin-1 or tumor necrosis factor-α antagonists do not inhibit graft-versus- host disease induced across the major histocompatability barrier in mice. Transplantation 1995; 60: 1371-1374.
42. Godfrey, DI, Gately MK, Hakimi J et al. IL-12 influences intrathytnic T cell development. J Immunol 1994; 152: 2729-2735.
43. Tare NS, Bowen S. Warrier RR et al. Administration of recombinant interleukin-12 to mice suppresses hematopoiesis in the bone marrow but enhances hematopoiesis in the spleen. J Interferon Cytokine Res 1995; 15: 377-383.
44. Krenger W, Falzarano G, Delmonte J et al. Interferon-γ surpresses T-cell proliferation to mitogen via the nitric oxide pathway during experimental acute graft-versus-host disease. Blood 1996; 88: 1113-1121.
45. Maier T, Holda JH, Claman HN. Murine natural suppressor cells in the newborn, in bone marrow, and after cyclophosphamide. Genetic variation and dependence on IFN-γ. J Immunol 1989; 143: 491-498.
46. + cell lines. Cell Immunol 1990; 127: 478-493.
47. - surface phenotype and the alpha, beta heterodimer of the T cell antigen receptor. J Immunol 1989; 143: 1118-1122.
48. Ishikawa H, Kubota E, Wilkinson NM, Saiko K. Modulation of F1 cytotoxic potential by GVHR: suppression of cytotoxic T cell responses in F1 mice correlates with F1 inability to resist the proliferation of GVHR-inducing parental T lymphocytes. J Immunol 1982; 129: 1181-1188.
49. Schmidt-Wolf IGH, Dejbakhsh-Jones S, Ginzton N et al. T- cell subsets and suppressor cells in human bone marrow. Blood 1992; 12: 3242-3250.
50. Strober S, Palathumpat V, Schwadron R, Hertel-Wulff B. Cloned natural suppressor cells prevent lethal graft-vs-host disease. J Immunol 1987; 138: 699-703.
51. Blaise D, Stoppa AM, Viens P et al. Intensive immunotherapy with recombinant IL2 after autologous bone marrow transplantation is associated with a high incidence of bacterial infections. Bone Marrow Transplant 1992; 10: 193-195.
52. Gottlieb DJ, Prentice HG, Heslop HE et al. IL-2 infusion abbrogates humoral immune responses in humans. Clin Exp Immunol 1992; 87: 493-498.
53. Robinson N, Sanders JE, Benyunes MC et al. Phase I trial of interleukin-2 after unmodified HLA-matched sibling bone marrow transplantation for children with acute leukemia. Blood 1996; 87: 1249-1254.
54. Paul WE, Seder RA. Lymphocyte responses and cytokines (review). Cell 1994; 76: 241-251.